Zacks Research Estimates Novavax FY2027 Earnings

Novavax, Inc. (NASDAQ:NVAX) – Stock analysts at Zacks Research issued their FY2027 earnings estimates for Novavax in a report issued on Thursday, March 20th. Zacks Research analyst S. Ganoria anticipates that the biopharmaceutical company will post earnings per share of $0.54 for the year. The consensus estimate for Novavax’s current full-year earnings is ($1.46) per share.

Several other research firms also recently commented on NVAX. HC Wainwright reiterated a “buy” rating and issued a $19.00 price objective on shares of Novavax in a research note on Tuesday, December 10th. BTIG Research initiated coverage on shares of Novavax in a research report on Friday, February 28th. They set a “buy” rating and a $19.00 target price for the company. Finally, TD Cowen raised shares of Novavax to a “hold” rating in a research report on Thursday, February 27th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $18.00.

Novavax Price Performance

NVAX opened at $7.69 on Monday. Novavax has a fifty-two week low of $3.81 and a fifty-two week high of $23.86. The company’s 50-day moving average is $8.23 and its 200 day moving average is $9.46. The firm has a market capitalization of $1.24 billion, a P/E ratio of -3.40, a PEG ratio of 2.85 and a beta of 2.92.

Novavax (NASDAQ:NVAX) last posted its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.51) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.24. The company had revenue of $88.31 million during the quarter, compared to the consensus estimate of $85.48 million. During the same quarter in the prior year, the business earned ($1.44) EPS.

Insider Activity at Novavax

In related news, Director James F. Young sold 5,400 shares of the firm’s stock in a transaction dated Tuesday, December 31st. The stock was sold at an average price of $8.00, for a total transaction of $43,200.00. Following the transaction, the director now directly owns 51,760 shares of the company’s stock, valued at approximately $414,080. This trade represents a 9.45 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. 1.00% of the stock is currently owned by insiders.

Institutional Trading of Novavax

Several institutional investors have recently added to or reduced their stakes in NVAX. GF Fund Management CO. LTD. purchased a new position in Novavax in the 4th quarter worth approximately $27,000. Spire Wealth Management purchased a new stake in shares of Novavax during the fourth quarter worth about $29,000. New Age Alpha Advisors LLC bought a new stake in shares of Novavax in the fourth quarter worth about $35,000. KBC Group NV raised its position in Novavax by 97.0% during the 4th quarter. KBC Group NV now owns 7,954 shares of the biopharmaceutical company’s stock valued at $64,000 after purchasing an additional 3,917 shares during the last quarter. Finally, TigerOak Management L.L.C. purchased a new stake in Novavax in the 4th quarter worth approximately $86,000. 53.04% of the stock is currently owned by hedge funds and other institutional investors.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.